TP53 and breast cancer: They report an association between ER−/PR+ status with biomarkers of poor prognosis, such as positive p53 and basal cytokeratins as well as reduced E-cadherin expression, and emphasise that women with ER−/PR+ breast cancer tend to have unfavourable outcomes compared to those with ER+/PR+ status [3, 25, 26].